Wall Street analysts who watch the cancer drug developer closely think it could rocket higher.
These stocks could rocket higher, but they also present significant risks.
Several well-regarded funds run by famous billionaire investors bought shares of 23andMe during the last three months of 2023.
/CNW/ - Find Therapeutics Inc., a biopharmaceutical company focused on the development of innovative therapies for autoimmune diseases, today announced that...
The renowned brokerage firm weighed in on its top stock picks from the European market, which could offer investors better value than the outsized GRANOLAS group of equities at current levels.
GSK's stock has been a poor performer for years. But recently, the pharma stock keeps setting new 52-week highs, thanks to its blockbuster vaccines.
Growth stocks are getting ready for a comeback year in 2024, and these two under-the-radar stocks have solid financials and significant upside potential.
Unlike many of its peers, GSK just reported a big year-over-year jump in vaccine sales - and there's more growth to come, as the pharmaceutical company expands both its pipeline and the geographical reach...
The world is a big place, and many great companies are based outside our U.S. borders.
Pharma stock GSK is a remedy for the winter blahs with a low beta, a high yield, and value for investors. Sales of new drug Arexvy underpin results.